EMAIL THIS PAGE TO A FRIEND

Journal of neuroimmunology

Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.


PMID 25262156

Abstract

Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD) as immunoadsorbent. We showed that two different immunoadsorbents, very efficiently and selectively depleted the MuSK antibodies from all tested sera, were stable during the procedure and were reusable. Furthermore, animal experiments showed that the treatment has no toxic effects to the animals. We conclude that the MuSK-ECD-mediated immunoadsorption can be used as an efficient antigen-specific therapy for MuSK-MG.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C0768
Cyclophosphamide monohydrate, bulk package
C7H15Cl2N2O2P · H2O
C7397
Cyclophosphamide monohydrate, ISOPAC®
C7H15Cl2N2O2P · H2O
93813
Cyclophosphamide monohydrate, analytical standard
C7H15Cl2N2O2P · H2O